TriSalus Life Sciences Inc.
TLSI | NASDAQ
$4.90
-$0.08 (-1.61%)
Sep 22, 2026, 11:50 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 45.15M | 29.43M | 18.51M | 12.4M | 8.4M | n/a |
Cost of Revenue | 6.97M | 4.1M | 2.61M | 2.26M | 1.19M | n/a |
Gross Profit | 38.19M | 25.33M | 15.91M | 10.14M | 7.21M | n/a |
Operating Income | -26.95M | -36.17M | -54.48M | -36.44M | -24.03M | -108.49K |
Interest Income | 555K | 404K | 431K | 180K | n/a | 3.3K |
Pretax Income | -39.22M | -30.04M | -59.35M | -47.18M | -28.84M | -711.39K |
Net Income | -39.23M | -33.23M | -59.36M | -47.19M | -28.85M | -31.83M |
Selling & General & Admin | 50.17M | 43.81M | 40.55M | 25.22M | 17.02M | 108.49K |
Research & Development | 14.97M | 17.69M | 29.84M | 21.36M | 14.22M | n/a |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 65.13M | 61.49M | 70.38M | 46.58M | 31.24M | 108.49K |
Interest Expense | 5.54M | 3.09M | 16K | 1K | 1.76M | n/a |
Selling & Marketing Expenses | 28.71M | 25.84M | 17.03M | 12.74M | 8.26M | n/a |
Cost & Expenses | 72.1M | 65.6M | 72.99M | 48.84M | 32.43M | 108.49K |
Income Tax Expense | 7K | 6K | 9K | 9K | 3K | n/a |
Shares Outstanding (Basic) | 49.19M | 26.5M | 26.47M | 29.61M | 31.25M | 30.56M |
Shares Outstanding (Diluted) | 37.9M | 26.5M | 26.47M | 29.61M | 31.25M | 30.56M |
EPS (Basic) | -1.84 | -1.25 | -2.23 | -1.59 | -0.92 | -0.02 |
EPS (Diluted) | -1.84 | -1.25 | -2.23 | -1.59 | -0.92 | -0.02 |
EBITDA | -33.05M | -32.39M | -58.65M | -46.76M | -26.62M | -711.39K |
EBIT | -33.68M | -33.13M | -59.34M | -47.18M | -27.08M | -711.39K |
Depreciation & Amortization | 626K | 744K | 684K | 414K | 464K | n/a |
Add to Watchlist
Select watchlists to add or remove TLSI